]>
IRCT20190727044343N3 IRCT 2020-06-12 Mazandaran University of Medical Sceinces ANIF1 effect on COVID-19 ANIF1 Evaluation of ANIF1 antiviral drug in COVID-19 patients: A Randomized Clinical Trial 2020-06-09 anticipated 60 Complete https://irct.ir/trial/47062 interventional Randomization: Randomized, Blinding: Double blinded, Placebo: Used, Assignment: Parallel, Purpose: Treatment, Randomization description: patients will be assigned one in between and randomly into two groups with accidental code, Blinding description: Patients will receive same taste and smell syrups, one with ANIF1 and other with multivitamin and chloroquine. Eligible patients are selected and introduced to the nurse to deliver the drug package, and the nurse gives one of the packages, respectively. The package includes one syrup in two. It is an antiviral drug with placebo tablets and another multivitamin and chloroquine syrup. Patients and researchers are unaware of the contents of the package. 2-3 COVID-19. Intervention 1: Intervention group: ANIF1 with specific doses of 10 cc as an oral syrup, 2 times a day for 7 days. Intervention 2: Control group: standard medication regimen according to the national standard protocolAND multivitamin syrup as placebo. Yes - There is a plan to make this available What will be shared: Data will be Released after the article is published When: after study conduction To whom: health care workers Conditions: for further investigation and therapeutic uses Where to obtain: Person in charge for study How to obtain: official letter Comments:
public Lotfollah Davoodi
Ghaemshahr Rasi Hospital
Sari Iran (Islamic Republic of) 4816633131 +98 11 4221 8231 lotfdavoodi@yahoo.com Mazandaran University of Medical Sciences scientific Lotfollah Davoodi
Ghaemshahr Rasi Hospital
Sari Iran (Islamic Republic of) 4816633131 +98 11 4221 8231 lotfdavoodi@yahoo.com Mazandaran University of Medical Sciences Iran (Islamic Republic of) COVID-19 diagnosis based on Lung Ct-Scan COVID-19 diagnosis based on RT-PCR Lymphopenia less than 1100 fever more than 38 degrees Positive CRP Positive respiratory symptoms Gastroitestinal symptms 18 years 65 years Both intubated patients with severe respiratory disease patients with severe co-morbidity and end stage disease Oral intolerance onset of symptoms more than 10 days pregnant women severe Immuncompromised patients U07.1 COVID-19, virus identified Treatment - Drugs Treatment - Drugs Intervention group: ANIF1 with specific doses of 10 cc as an oral syrup, 2 times a day for 7 days Control group: standard medication regimen according to the national standard protocolAND multivitamin syrup as placebo RT-PCR test.IL-6,CRP. Timepoint: at the beginning and end of study. Method of measurement: nasopharyngeal swab. Lung CT-Scan. Timepoint: at the beginning and end of study. Method of measurement: CT-Scan. Inflammatory biomarkers IL6,CRP. Timepoint: at the beginning and end of study. Method of measurement: blood test. kimia cell pajoohan Approved 2020-04-11 Ethics committee of Mazandaran University of Medical Sciences Moallem Sari Mazandaran Iran (Islamic Republic of)